Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07405164 · ClinicalTrials.gov registry record · Phase 3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
NCT07405164 is a Phase 3 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 450 participants.
The verdict
NCT07405164, a Phase 3 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.
Interventions
- DRUG Belzutifan
- DRUG Nivolumab
- DRUG Cabozantinib
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2034-01-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07405164
The ClinicalTrials.gov registry entry for NCT07405164 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Belzutifan is the first listed.
NCT07405164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07405164 about?
NCT07405164 is a clinical study titled "Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)". Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the b...
What is the current status of trial NCT07405164?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2026-03-23. Estimated completion is 2034-01-14.
What interventions are being tested in trial NCT07405164?
The interventions under investigation include: Belzutifan (DRUG), Nivolumab (DRUG), Cabozantinib (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT07405164?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.